Development of interpretive criteria and quality control limits for broth microdilution and disk diffusion antimicrobial susceptibility testing of Streptococcus pneumoniae. 1994

J H Jorgensen, and J M Swenson, and F C Tenover, and M J Ferraro, and J A Hindler, and P R Murray
Department of Pathology, University of Texas Health Science Center, San Antonio 78284-7750.

A five-center collaborative study was undertaken to develop quality control and specific interpretive criteria for susceptibility testing of Streptococcus pneumoniae against 12 antimicrobial agents. MICs were determined for 248 pneumococcal clinical isolates (with an emphasis on resistant strains) by use of the National Committee for Clinical Laboratory Standards (NCCLS)-recommended broth microdilution procedure incorporating lysed horse blood-supplemented Mueller-Hinton broth. NCCLS disk diffusion testing was also performed for each isolate by using Mueller-Hinton sheep blood agar incubated in 5% CO2. Repetitive testing of S. pneumoniae ATCC 49619 with different sources and lots of media and disks allowed development of quality control ranges which encompassed approximately 95% of MIC and zone size values observed in the study. Good intra- and interlaboratory reproducibilities were seen with these testing methods and all of the drugs examined. On the basis of the results of this study, MIC interpretive criteria are proposed for 11 agents. Comparisons of MICs and disk diffusion zone sizes allowed disk diffusion zone size interpretive criteria to be proposed for five drugs and confirmed the use of the oxacillin disk test for prediction of penicillin susceptibility among pneumococci. Excessive numbers of minor-category interpretive errors precludes recommendation at this time of the disk diffusion method for testing of pneumococci against five of the drugs. Use of these proposed quality control and interpretive criteria should provide for reproducible test results and allow recognition of recently emerging resistance among pneumococcal clinical isolates.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D011786 Quality Control A system for verifying and maintaining a desired level of quality in a product or process by careful planning, use of proper equipment, continued inspection, and corrective action as required. (Random House Unabridged Dictionary, 2d ed) Control, Quality,Controls, Quality,Quality Controls
D004058 Diffusion The tendency of a gas or solute to pass from a point of higher pressure or concentration to a point of lower pressure or concentration and to distribute itself throughout the available space. Diffusion, especially FACILITATED DIFFUSION, is a major mechanism of BIOLOGICAL TRANSPORT. Diffusions
D013296 Streptococcus pneumoniae A gram-positive organism found in the upper respiratory tract, inflammatory exudates, and various body fluids of normal and/or diseased humans and, rarely, domestic animals. Diplococcus pneumoniae,Pneumococcus

Related Publications

J H Jorgensen, and J M Swenson, and F C Tenover, and M J Ferraro, and J A Hindler, and P R Murray
July 1983, Antimicrobial agents and chemotherapy,
J H Jorgensen, and J M Swenson, and F C Tenover, and M J Ferraro, and J A Hindler, and P R Murray
January 1989, Journal of clinical microbiology,
J H Jorgensen, and J M Swenson, and F C Tenover, and M J Ferraro, and J A Hindler, and P R Murray
November 1987, Journal of clinical microbiology,
J H Jorgensen, and J M Swenson, and F C Tenover, and M J Ferraro, and J A Hindler, and P R Murray
March 1990, Journal of clinical microbiology,
J H Jorgensen, and J M Swenson, and F C Tenover, and M J Ferraro, and J A Hindler, and P R Murray
January 1991, Diagnostic microbiology and infectious disease,
J H Jorgensen, and J M Swenson, and F C Tenover, and M J Ferraro, and J A Hindler, and P R Murray
January 1992, Diagnostic microbiology and infectious disease,
J H Jorgensen, and J M Swenson, and F C Tenover, and M J Ferraro, and J A Hindler, and P R Murray
September 1987, Journal of clinical microbiology,
J H Jorgensen, and J M Swenson, and F C Tenover, and M J Ferraro, and J A Hindler, and P R Murray
March 1985, Journal of clinical microbiology,
J H Jorgensen, and J M Swenson, and F C Tenover, and M J Ferraro, and J A Hindler, and P R Murray
May 2022, The Journal of antimicrobial chemotherapy,
J H Jorgensen, and J M Swenson, and F C Tenover, and M J Ferraro, and J A Hindler, and P R Murray
January 1989, Diagnostic microbiology and infectious disease,
Copied contents to your clipboard!